[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note",
    "summary": "Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=a69361689d30021d6640f60192a78831f13a20a63901ec79941077b97d49e21d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758150003,
      "headline": "Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note",
      "id": 136797743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=a69361689d30021d6640f60192a78831f13a20a63901ec79941077b97d49e21d"
    }
  },
  {
    "ts": null,
    "headline": "Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis",
    "summary": "Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Congress SAN FRANCISCO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company’s ongoing rese",
    "url": "https://finnhub.io/api/news?id=efd62465643dcb893160d1f4a4ee84eb916a4ef5d4b994ece8b4e0381032f923",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758110400,
      "headline": "Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis",
      "id": 136787609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Congress SAN FRANCISCO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company’s ongoing rese",
      "url": "https://finnhub.io/api/news?id=efd62465643dcb893160d1f4a4ee84eb916a4ef5d4b994ece8b4e0381032f923"
    }
  }
]